Brief Research Report
Published on 22 Apr 2021
Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
in Inflammation Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2021.650295
- 8,863 views
- 39 citations

